An open label trial of OZ101 as an add-on therapy for the treatment of type 2 diabetes mellitus in patients on sulphonylurea monotherapy.
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 22 Sep 2016
At a glance
- Drugs OZ 101 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors OzStar Therapeutics
- 06 Sep 2016 Status changed from recruiting to not yet recruiting.
- 06 Sep 2016 Planned End Date changed from 31 Dec 2015 to 28 Feb 2017.
- 06 Sep 2016 Planned initiation date changed from 1 Aug 2015 to 31 Oct 2016.